Black Diamond Therapeutics Inc
BDTX2.600USD
+0.060+2.36%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
148.05MMarket Cap
6.86P/E TTM
More Details of Black Diamond Therapeutics Inc Company
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Inc Info
Ticker SymbolBDTX
Company nameBlack Diamond Therapeutics Inc
IPO dateJan 30, 2020
CEOVelleca (Mark A)
Number of employees24
Security typeOrdinary Share
Fiscal year-endJan 30
Address245 First Street, 18Th Floor
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16174175868
Websitehttps://www.blackdiamondtherapeutics.com/
Ticker SymbolBDTX
IPO dateJan 30, 2020
CEOVelleca (Mark A)
Company Executives of Black Diamond Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
81.44K
+5.56%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
26.36K
+17.07%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
81.44K
+5.56%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
26.36K
+17.07%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Other
48.86%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Other
48.86%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.99%
Investment Advisor/Hedge Fund
20.59%
Venture Capital
19.08%
Hedge Fund
7.50%
Research Firm
1.42%
Individual Investor
0.99%
Pension Fund
0.02%
Other
19.41%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
251
45.27M
104.04%
+4.70K
2025Q3
261
45.26M
106.75%
+270.69K
2025Q2
263
45.72M
119.11%
-2.33M
2025Q1
244
48.05M
134.35%
-28.07M
2024Q4
236
55.25M
127.86%
-855.91K
2024Q3
237
56.09M
121.86%
+1.99M
2024Q2
230
54.06M
101.77%
+8.09M
2024Q1
233
46.69M
117.14%
-13.89M
2023Q4
222
46.16M
104.70%
+1.30M
2023Q3
240
44.37M
104.97%
-4.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
10.51M
18.46%
+112.89K
+1.09%
Jun 30, 2025
Versant Ventures
6.21M
10.9%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.60M
9.84%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
4.45M
7.81%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.10M
3.69%
-253.80K
-10.77%
Jun 30, 2025
Tang Capital Management, LLC
2.07M
3.64%
--
--
Jun 30, 2025
Marshall Wace LLP
737.88K
1.3%
+737.88K
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Jun 30, 2025
Millennium Management LLC
944.85K
1.66%
-159.06K
-14.41%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Fidelity Enhanced Small Cap ETF
0.05%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
DFA Dimensional US Small Cap Value ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Health Innovation Active ETF
0%
Vanguard US Momentum Factor ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
Fidelity Enhanced Small Cap ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
DFA Dimensional US Small Cap Value ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Vanguard US Momentum Factor ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Black Diamond Therapeutics Inc?
The top five shareholders of Black Diamond Therapeutics Inc are:
T. Rowe Price Investment Management, Inc. holds 10.51M shares, accounting for 18.46% of the total shares.
Versant Ventures holds 6.21M shares, accounting for 10.90% of the total shares.
Vestal Point Capital, LP holds 5.60M shares, accounting for 9.84% of the total shares.
New Enterprise Associates (NEA) holds 4.45M shares, accounting for 7.81% of the total shares.
The Vanguard Group, Inc. holds 2.10M shares, accounting for 3.69% of the total shares.
T. Rowe Price Investment Management, Inc. holds 10.51M shares, accounting for 18.46% of the total shares.
Versant Ventures holds 6.21M shares, accounting for 10.90% of the total shares.
Vestal Point Capital, LP holds 5.60M shares, accounting for 9.84% of the total shares.
New Enterprise Associates (NEA) holds 4.45M shares, accounting for 7.81% of the total shares.
The Vanguard Group, Inc. holds 2.10M shares, accounting for 3.69% of the total shares.
What are the top three shareholder types of Black Diamond Therapeutics Inc?
The top three shareholder types of Black Diamond Therapeutics Inc are:
T. Rowe Price Investment Management, Inc.
Versant Ventures
Vestal Point Capital, LP
T. Rowe Price Investment Management, Inc.
Versant Ventures
Vestal Point Capital, LP
How many institutions hold shares of Black Diamond Therapeutics Inc (BDTX)?
As of 2025Q4, 251 institutions hold shares of Black Diamond Therapeutics Inc, with a combined market value of approximately 45.27M, accounting for 104.04% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.71%.
What is the biggest source of revenue for Black Diamond Therapeutics Inc?
In --, the -- business generated the highest revenue for Black Diamond Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
